Sep 2026· Future Journal of Pharmaceuticals and Health Sciences· Vol 6, pp. 15-28· 0 citations
TL;DR
The many advantages of AI in drug development are highlighted in this paper, including increased accuracy, reduced risks, and increased efficiency, including increased accuracy, reduced risks, and increased efficiency.
Abstract
Artificial intelligence (AI) has transformed drug discovery and development by streamlining research processes, reducing development time and costs, and improving the efficiency and success of identifying promising therapeutic candidates. Drug targets can be quickly identified, compound efficacy may be predicted, and drug design can be optimized thanks toartificial intelligence (AI), which assesses massive datasets usingNatural language processing (NLP), machine learning (ML), and deep learning (DL).Through better patient recruitment and data analysis, it refines clinical trial designs and speeds uplead detection using toxicity, potential adverse effects, and pharmacokinetic predictions.The many advantages of AI in drug development are highlighted in this pa per, including increased accuracy, reduced risks, and increased efficiency. Important issues including data quality, model interpretability, and regulatory obstacles are also covered. Improving data will be necessary for future developments in AI - powered d rug discovery.standardization, encouraging openness in the creation of AI models, and bolstering cooperation between pharmaceutical specialists and AI researchers. By tackling these issues, AI has the power to completely transform healthcare by giving pati ents safer, more efficient, and more reasonably priced medications.
This study reviews AI-driven drug discovery methods, presents a structured AI pipeline from data collection to candidate selection, and evaluates performance using metrics such as prediction accuracy, screening efficiency, lead optimization success, and toxicity reduction.
Joseph Robin· International Journal of Mod...· 0 citations
Artificial Intelligence (AI) is rapidly transforming pharmaceutical research and drug development. The
traditional process of discovering and developing new medicines is time-consuming, expensive and associated with a high
rate of failure. AI, including machine learning, deep learning, natural language processing and g...
Rajashree Somnath Chorgade, Srushti Dipak Nevase, Shubham Hanumant Dhavale et al.· International Journal of Inn...· 0 citations
It is essential to view AI technologies as an instrumental but supplementary part of decision-making in pharmaceutical research and development rather than a fully independent alternative to traditional hit- and lead-discovery strategies.
Saikat Biswas, Somenath Bhattacharya, Soumallya Chakraborty· International Journal for Re...· 0 citations
Simple Summary Only 4.1% of potential cancer therapeutics reach the clinic despite taking roughly fourteen years to develop at a cost of more than a billion USD. Large datasets and artificial intelligence (AI) are promising new tools to improve the odds. Cancer drug discovery produces enormous amounts of data related t...
Fakhar U. Singhera, J. Overhulse, Terrence M. Lee et al.· Cancers· 0 citations
Traditional drug development suffers from high costs, low success rates, and patient response variability. Precision drug discovery seeks to overcome these limitations by targeting specific genetic and molecular mechanisms but faces challenges in integrating cross-scale, multimodal biomedical data. Recent advances in a...
AutoML mitigates issues by automating key stages of the ML pipeline data preprocessing, model selection, hyperparameter tuning, and evaluation thereby enhancing scalability and reducing dependence on domain expertise.
S. Aydın· ITU Journal of Metallurgy an...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.